| Patient | Wilma Rudolph |
|---|---|
| Date of birth | 1972-06-23 |
| Identifiers | MRN HR-ML036-SYN; SSN (made up) 000-36-5170 |
| Document date | 2026-09-14 |
| Author | Gloria Haynes-Whitaker, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Review at the end of six weeks of radiotherapy with daily temozolomide. [S]
Ms. Rudolph returns on the first weekday after her last radiotherapy fraction. She completed all 30 fractions and took temozolomide every day without a break, the 42nd and last dose last night. Nausea was mild and controlled by ondansetron before each dose. She stopped dexamethasone a month ago and her fingerstick glucose readings came back below 120 mg/dL, so she stopped checking. She is more tired each week, sleeps after lunch and has worked only a few hours a day for the past two weeks. Her hair has fallen out over the treated area and the skin there is pink. She has had no headache, seizure, change in speech, weakness, fever, bruising, cough or fall. The weekly blood counts at the radiation clinic were normal in the first five weeks; the week 6 count was not drawn. She has read about tumor-treating fields and wants to talk about them. She has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Treatment | Radiotherapy 60 Gy in 30 fractions and 42 days of temozolomide completed on schedule |
| Steroid | Off dexamethasone for a month; glucose normal |
| Symptoms | Fatigue, mild nausea, hair loss and pink skin over the field |
| Blood counts | Normal for five weeks; week 6 not drawn |
| Her question | Whether to use tumor-treating fields |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Fatigue, worse each week; no fever; weight down 2.2 kg since the steroid stopped |
| Gastrointestinal | Positive | Mild nausea after the doses, controlled; no vomiting; no constipation |
| Integumentary | Positive | Hair loss over the treated area; pink scalp without blisters |
| Neurological | Negative | No headache, seizure, speech change or new weakness |
| Hematologic and lymphatic | Negative | No bruising, nosebleeds or gum bleeding |
| Respiratory | Negative | No cough or breathlessness |
| Psychiatric | Positive | Low in energy and sometimes discouraged; PHQ-9 8, mostly from tiredness and sleep; no thoughts of self-harm |
7 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a day | Two tablets every 6 hours as needed | Oral route | 2026-06-29 | active | S |
| Dexamethasone 4 mg oral tablet, one tablet twice a day with food, for symptomatic vasogenic edema, until surgery | One tablet twice a day with breakfast and lunch | Oral route | 2026-06-30 to 2026-07-08 | completed | S |
| Famotidine 20 mg oral tablet, one tablet twice a day while taking dexamethasone | One tablet twice a day | Oral route | 2026-06-30 to 2026-08-12 | completed | S |
| Dexamethasone 2 mg oral tablet, one tablet twice a day after surgery, tapering | One tablet twice a day | Oral route | 2026-07-10 to 2026-07-29 | completed | S |
| Dexamethasone 2 mg oral tablet: one tablet daily for one week, then half a tablet daily for one week, then stop | One tablet daily for a week, then half a tablet daily for a week | Oral route | 2026-07-29 to 2026-08-12 | completed | S |
| Temozolomide 140 mg oral capsule, 140 mg (75 mg/m2) by mouth daily at bedtime on an empty stomach, seven days a week for 42 days from the first day of radiotherapy | Once daily at bedtime, seven days a week, for 42 days | Oral route | 2026-08-03 to 2026-09-13 | completed | S |
| Sulfamethoxazole 800 mg and trimethoprim 160 mg oral tablet, one tablet three times a week (Monday, Wednesday and Friday) to prevent Pneumocystis pneumonia | One tablet on Monday, Wednesday and Friday | Oral route | 2026-08-03 | active | S |
| Ondansetron 8 mg oral tablet, one tablet 30 to 60 minutes before each temozolomide dose, and every 8 hours as needed for nausea | Before each temozolomide dose; every 8 hours as needed | Oral route | 2026-08-03 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-09-14 | Body height | 180 | cm | S |
| 2026-09-14 | Body weight | 67.2 | kg | S |
| 2026-09-14 | Body mass index (BMI) [Ratio] | 20.7 | kg/m2 | S |
| 2026-09-14 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-09-14 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-09-14 | Heart rate | 80 | /min | S |
| 2026-09-14 | Respiratory rate | 16 | /min | S |
| 2026-09-14 | Body temperature | 36.8 | Cel | S |
| 2026-09-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-09-14 | Hemoglobin [Mass/volume] in Blood | 11.9 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-09-14 | Leukocytes [#/volume] in Blood by Automated count | 3.6 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 2026-09-14 | Neutrophils [#/volume] in Blood by Automated count | 2.4 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2026-09-14 | Lymphocytes [#/volume] in Blood by Automated count | 0.5 | 10*3/uL | 1-4 10*3/uL | Low | S |
| 2026-09-14 | Platelets [#/volume] in Blood by Automated count | 112 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 2026-09-14 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-09-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 88 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-09-14 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 48 | U/L | 7-35 U/L | High | S |
| 2026-09-14 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 39 | U/L | 8-35 U/L | High | S |
| 2026-09-14 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-09-14 | Glucose [Mass/volume] in Serum or Plasma | 96 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-09-14 | Karnofsky Performance Status score | 80 | {score} | S | ||
| 2026-09-14 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S |
Vital signs recorded on 2026-09-14; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Tired but well; weight 67.2 kg; blood pressure 118/74, pulse 80, temperature 36.8 °C |
| Head | Alopecia over the left frontal field; grade 1 radiation dermatitis; incision healed |
| Mouth | No ulcers or thrush |
| Skin | No bruising or petechiae |
| Neurological | Speech fluent; strength full in all four limbs; finger tapping equal; gait steady |
| Extremities | No leg swelling or calf tenderness |
| Psychiatric | Tired, warm and engaged |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Three weeks of headaches on waking, with ten days of pauses in finding words and clumsiness of the right hand, in a previously well woman of 54: an intracranial lesion must be excluded. MRI of the brain with and without contrast booked for tomorrow morning, and neuro-oncology review booked | resolved | confirmed | R29.818 | S — Synthetic presenting problem; no symptom of her real illness was made public. Superseded when the MRI showed a brain mass. |
| Left posterior frontal ring-enhancing mass, 3.8 cm, with central necrosis, surrounding edema and 5 mm midline shift, next to the language and motor areas; presumed high-grade glioma, with no primary cancer elsewhere on CT; tissue diagnosis pending | resolved | confirmed | D49.6 | S — Synthetic imaging diagnosis before surgery; superseded by the pathology. |
| Glioblastoma, IDH-wildtype, CNS WHO grade 4, left posterior frontal lobe, MGMT promoter methylated, after gross total resection of the enhancing tumor; synthetic modern detail linked to her publicly reported brain cancer | active | confirmed | C71.1 | S — Synthetic histology, molecular result and location; brain cancer is documented as the cause of her death (D), and nothing more about it was made public. |
| Late effects of childhood poliomyelitis: paralysis of the left leg in early childhood, treated with a metal brace, a special shoe, massage and heat, with full recovery of walking by about age 12 and a later career as an Olympic sprinter; no new weakness, fatigue or pain now to suggest post-polio syndrome | active | confirmed | B91 | S — Documented childhood polio (D); the current absence of new symptoms is synthetic. |
| Vasogenic cerebral edema around the left frontal mass, with 5 mm midline shift, causing headache and contributing to the language and right-hand symptoms; treated with dexamethasone | active | confirmed | G93.6 | S — Synthetic finding on the first MRI. |
| Steroid-induced hyperglycemia on dexamethasone: random glucose 168 mg/dL, with an A1c of 5.6% before steroids | resolved | confirmed | R73.9 | S — Synthetic common effect of dexamethasone; resolved after the taper. |
| Lymphopenia from temozolomide, grade 2 (absolute lymphocytes 0.5 x 10^3/uL at the end of chemoradiation): Pneumocystis prophylaxis continues until recovery to grade 1 or better | active | confirmed | D72.810 | S — Synthetic common effect of daily temozolomide with radiotherapy. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count with neutrophils, lymphocytes and platelets | Weekly during concurrent temozolomide | Completed today | Hemoglobin 11.9 g/dL, white cells 3.6, neutrophils 2.4, lymphocytes 0.5, platelets 112: grade 1 thrombocytopenia and grade 2 lymphopenia |
| Laboratory | Blood count in week 6 of concurrent treatment | Weekly during concurrent temozolomide | Deferred | A deviation: not drawn in the last week of radiotherapy because the clinic's standing order was set for the Monday, a holiday that week, and was not moved. No harm resulted: today's count, a week later, shows platelets 112 and neutrophils 2.4, above the levels that would have stopped temozolomide, and she had no bleeding or fever. Corrective action: today's count; future standing orders are tied to treatment days, not a weekday |
| Laboratory | Liver tests (ALT, AST, bilirubin) | Baseline, during treatment, before each cycle, and two to four weeks after the last dose | Completed today | ALT 48, AST 39 U/L (grade 1), bilirubin 0.6 mg/dL; recheck before cycle 1 |
| Laboratory | Kidney function and glucose | Each visit; glucose after a steroid course | Completed today | Creatinine 0.80 mg/dL, eGFR 88; glucose 96 mg/dL off dexamethasone |
| Laboratory | Hepatitis B, hepatitis C and HIV screening | Before chemotherapy | Up to date | All negative |
| Medication safety | Pneumocystis pneumonia prophylaxis | During concurrent temozolomide, and until lymphopenia is grade 1 or better | Completed today | Taken as prescribed without rash; continues for grade 2 lymphopenia |
| Medication safety | Antiemetic before temozolomide | Each dose | Completed today | Ondansetron effective; no vomiting |
| Imaging | MRI of the brain after chemoradiation | About four weeks after radiotherapy, as the new baseline | Ordered | In about three weeks; enhancement in the first three months may be treatment effect (pseudoprogression) and is read by RANO 2.0 |
| Examination | Neurologic examination (language, strength, gait) | Each visit | Completed today | No deficit; speech fluent; strength full |
| Examination | Radiation skin reaction and hair loss | Weekly during radiotherapy and at the end | Completed today | Grade 1 dermatitis; alopecia over the field |
| Medication safety | Seizure history and antiseizure drug need | Each visit | Not indicated | No seizure; no antiseizure drug |
| Examination | Signs of leg clot or pulmonary embolism | Each visit | Completed today | None |
| Survey | Performance status (Karnofsky) | Each visit | Completed today | Karnofsky 80, from fatigue |
| Self-management | Tumor-treating fields | Offered with adjuvant temozolomide for supratentorial glioblastoma | Completed today | Benefits, daily wear and skin effects discussed; she chose to start them with cycle 1 |
| Referral | Palliative care | Early, alongside cancer treatment, for a serious illness with a high symptom burden | Referred | Outpatient consultation booked in two weeks |
| Self-management | Falls, leg strength and late effects of polio | Each visit | Completed today | No falls; home exercises at a gentler level; cane on uneven ground |
| Survey | Distress and depression screen (PHQ-9) | At diagnosis, each treatment phase, and when symptoms change | Completed today | PHQ-9 8, mostly from fatigue and sleep; no thoughts of self-harm |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers (2026); Weller M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 2021;18(3):170-186 (PMID 33293629) (2021); Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-996 (PMID 15758009) (2005); Stupp R, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma (EF-14). JAMA 2017;318(23):2306-2316 (PMID 29260225) (2017); Wen PY, et al. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. J Clin Oncol 2023 (PMID 37774317) (2023); TEMODAR (temozolomide) capsules, prescribing information (2026); Walbert T, et al. SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol 2021;23(11):1835-1844 (PMID 34174071) (2021); Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (PMID 37075273) (2023); Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024;42(19):2336-2357 (PMID 38748941) (2024); Farbu E, et al. EFNS guideline on diagnosis and management of post-polio syndrome. Eur J Neurol 2006;13(8):795-801 (PMID 16879288) (2006); CMID: Clinical Monitoring Intelligence Database, depression monograph (2026); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: MRI in about three weeks; palliative care in two weeks. Review with the MRI result on the day adjuvant temozolomide starts. Call for fever, bruising, bleeding, a seizure, headache or new weakness. Next scheduled visit 2026-10-09: post-chemoradiation MRI result, day 1 of adjuvant temozolomide, the start of tumor-treating fields, and the palliative care plan. [S]